UHPLC Analysis of Iloperidone and Its Primary Metabolite Hydroxyiloperidone on Ascentis® Express C18

CONDITIONS
column
Ascentis Express C18, 10 cm x 3.0 mm, I.D., 2.0 μm particles (50819-U)
mobile phase
[A] 10 mM ammonium formate in water, pH adjusted to 3.0 with formic acid [B] 0.1% formic acid in methanol
gradient
45% B for 2 min; to 80% B over 10 min; held at 80% B for 2 min
flow rate
0.5 mL/min
pressure
6500 psi (445 bar)
column temp.
35 °C
detector
UV, 275 nm
injection
2 μL
sample
50 μg/mL Iliperidone, 5 μg/mL hydroxyiliperidone in 10% methanol
Description
Analysis Note
Iloperidone is an atypical antipsychotic administered for the treatment of schizophrenia. The drug is marketed under the trade names Fanapt and Fanapta. Hydroxyiloperidone is a major metabolite of iloperidone. The metabolite is also pharmacologically active, possessing central nervous system (CNS) activity. Shown here is the rapid, efficient UHPLC separation of iloperidone and hydroxyiloperidone on a Fused-Core Ascentis Express C18 column. Cerilliant CRMs provided reliable quantification.
Legal Information
Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany